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Abstract Because of its multi-organ involvement, the syn-
drome of sepsis provides clinical challenges to a wide variety
of health care providers. While multi-organ dysfunction trig-
gered by sepsis requires general supportive critical care pro-
vided by intensivists, the impact of sepsis on renal function
and the ability of renal replacement therapies to modulate its
biologic consequences provide a significant opportunity for
pediatric nephrologists and related care providers to impact
outcomes. In this review, we aim to highlight newer areas of
understanding of the pathobiology of sepsis with special em-
phasis on those aspects of particular interest to pediatric ne-
phrology. As such, we aim to: (1) review the definition of
sepsis and discuss advances in our mechanistic understanding
of sepsis; (2) review current hypotheses regarding sepsis-
induced acute kidney injury (AKI) and describe its epidemi-
ology based on evolving definitions of AKI; (3) review the
impact of renal failure on the immune system, highlighting the
sepsis risk in this cohort and strategies that might minimize
this risk; (4) review how renal replacement therapeutic strat-
egies may impact sepsis-induced AKI outcomes. By focusing
the review on these specific areas, we have omitted other
important areas of the biology of sepsis and additional inter-
actions with renal function from this discussion; however, we
have aimed to provide a comprehensive list of references that
provide contemporary reviews of these additional areas.
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Defining “sepsis”
While the response of the human host to an invasive pathogen
has been recognized for centuries, it was only in the early
1990s that any attempt at developing a consensus definition
for sepsis (and septic shock) wasmade [1]. It was believed that
a standardized definition would afford accurate determination
of the epidemiology of sepsis and serve to identify patients
with sepsis for the purpose of study enrollment in clinical
trials. Thus, in 1992, participants of the American College of
Chest Physicians and Society of Critical Care Medicine
Consensus Conference first derived what remains the basis
for the most widely accepted definition for sepsis [1]. Nearly a
decade later, an international panel of experts in sepsis refined
the adult consensus definition of sepsis (and related terms) and
adapted the definitions for children [2]. The definition was
based on the clinical observations of tachycardia, tachypnea,
hyperthermia (or hypothermia) as well as laboratory evidence
of leukocytosis and/or significant bandemia (>10% bands in a
differential white blood cell count) in the setting of proven or
highly suspected infection. While these clinical findings
reflected the host’s systemic response to infection, it was clear
that similar responses could be observed without evidence or
involvement of a pathogen trigger (e.g., in response to pan-
creatitis, trauma, etc.). As a result, the terms “systemic inflam-
matory response syndrome” or SIRS was used to characterize
N. B. Blatt :M. M. Shanley
Division of Pediatric Nephrology, C.S. Mott Children’s Hospital at
the University of Michigan, Ann Arbor, MI, USA
S. Srinivasan
Department of Pediatrics, University of Wisconsin School of
Medicine and Public Health, Madison, WI, USA
T. Mottes
Division of Pediatric Nephrology, Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH, USA
T. P. Shanley (*)
Division of Pediatric Critical Care Medicine, C.S. Mott Children’s
Hospital at the University of Michigan, Building 400 2800 Plymouth
Road, Ann Arbor, MI 48109, USA
e-mail: tshanley@med.umich.edu
Pediatr Nephrol (2014) 29:2273–2287
DOI 10.1007/s00467-013-2677-3
this state of immune activation in which an infant or child
showed the presence of at least two of these four criteria, one
of which must be either hyper/hypothermia or leukocytosis
(Table 1). Numerous critical clinical conditions are associated
with SIRS criteria, so it has been argued that this definition is
not specific enough to provide any meaningful clinical dis-
tinction among triggering etiologies—both pathogen and non-
pathogen causes alike [3]. Nevertheless, the term “sepsis” is
applied to those states in which SIRS criteria are present in
response to an infection. The infection can be established
either by positive microbiology cultures, clear clinical evi-
dence of infection (such as a culture negative empyema) or
with strong clinical suspicion. When there is evidence of
inadequate end-organ perfusion (see criteria in Table 2)
resulting from this systemic response, the term “severe sepsis”
is applied. For pediatrics, severe sepsis encompasses cardio-
vascular dysfunction, though many use the specific descriptor
of septic shock to define sepsis associated with hypotension
(two distinct measurements<3rd percentile for age) after the
administration of at least 40 ml/kg of crystalloid or colloid
and/or other criteria (see Table 2).
Conventional management of pediatric sepsis/septic shock
has been reviewed elsewhere [4, 5], and so it will not be detailed
here. Current guidelines place an emphasis on early fluid re-
suscitation with isotonic fluids up to 60 ml/kg. If on-going
hypoperfusion or frank hypotension is still observed, the patient
is described to have ‘fluid-refractory shock’ and initiation of
inotropic support (either dopamine or low-dose [0.02–0.1 mcg/
kg/min] epinephrine) is recommended. If inadequate end-organ
perfusion is still evident, the patient is described as having
‘catecholamine-refractory shock’ and it behooves the clinician
to determine whether the patient is demonstrating ‘cold’ shock
or ‘warm’ shock. Cold shock is manifested by decreased per-
fusion characterized by delayed capillary refill (>3 s), and cool,
mottled extremities and is associated with low cardiac output
and elevated systemic vascular resistance—a common hemo-
dynamic pattern in children [6, 7]. ‘Warm shock,’ most com-
monly observed in adults, is characterized by flash capillary
refill, bounding peripheral pulses and a wide pulse pressure and
is associated with high to supranormal cardiac output with
significantly reduced systemic vascular resistance. It is impor-
tant to recognize that these hemodynamic states of fluid-
refractory, catecholamine-resistant shock can vary over time
such that real-time, bedside attention to the clinical hemody-
namic pattern is necessary. This recommended algorithmic
approach to managing pediatric shock is currently undergoing
its third iteration with plans to be published in 2014 [4].
Pathogenesis of sepsis
The ability to contain and eradicate invading pathogens has
enabled humans to evolve in a climate of numerous microbial
challenges. This fundamental function necessary for host
Table 1 Clinical and laboratory criteria for the systemic inflammatory
response syndrome (SIRS). Note: Patients must present with at least two
of the following and *must include either 1 or 4
1. *Temperature>38° C or<36° C (as determined by central temperature)
2. Heart rate>90th percentile for age
3. Respiratory rate >90th percentile for age, or hyperventilation to
PaCO2<32 torr
4. *White blood cell count >12,000 cells/mm3, or <4,000 cells/mm3
Table 2 Criteria for severe sepsis. Sepsis plus any one of the following:
1. Cardiovascular dysfunction:
Despite administration of isotonic intravenous fluid bolus of ≥40 ml/kg in
1 h: Decrease in blood pressure to <5th percentile for age or blood
pressure at <2 SDs below normal for age; or Need for vasoactive drug
to maintain blood pressure in the normal range (dopamine>5 mcg/kg/
min or dobutamine, epinephrine, or norepinephrine at any dose); or
Any two of the following
Unexplained metabolic acidosis (base deficit>5.0 mEq/l);
Increased arterial lactate at >2 times the upper limit of normal;
Oliguria (urine output<0.5 ml/kg per h);
Prolonged capillary refill (>5 s); or
Core-to-peripheral temperature differential of>3 °C
2. Respiratory
PaO2/FiO2<300 in absence of cyanotic heart disease or preexisting lung
disease; or
PaCO2>65 torr or 20 mm Hg over baseline PaCO2; or
Proven need or 0.5 FIO2 to maintain saturation at ≥92 %; or
Need for non-elective invasive or non-invasive mechanical ventilation
3. Neurologic
Glasgow Coma Score≤11; or
Acute change in mental status with a decrease in Glasgow Coma Score of
≥3 points from abnormal baseline
4. Hematologic
Platelet count<80,000/μl or a decline of 50 % in platelet count from




Serum creatinine level ≥2 times the upper limit of normal for age or
twofold increase in baseline creatinine level
6. Hepatic
Total bilirubin concentration≥4 mg/dl (excepting newborns); or
ALT 2 times upper limit of normal for age
Note: Criteria for septic shock
Sepsis with hypotension (two distinct measurements of blood pressure<3rd
percentile for age) after administration of 40 ml/kg of crystalloid or colloid, plus
any one of the following:
1. Requirement for inotropic or vasopressor support (excluding dopamine<5 μg/
kg/min)
2. Any of the cardiovascular diagnostic criteria for severe sepsis listed above
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survival is served by the immune system that has elegantly
evolved to contain and eradicate pathogens while preserving
physiologic integrity of the host. In the latter half of the 20th
century, combined clinical and basic science studies demon-
strated that pathogens (and/or their products) were responsible
for initiating a host immune response that resulted in SIRS.
While this response is typically well regulated by the host,
dysregulation of this local response can lead to tissue injury
and consequent organ dysfunction. Pediatricians are well
aware of the various inciting pathogens that can trigger this
physiologic response: Gram-negative and Gram-positive bac-
teria, viruses, fungi, and even protozoa. Failure to contain and/
or eradicate microbes leads to overwhelming, systemic spread
of pathogens (e.g., bacteremia) with subsequent release of
toxins (e.g., endo- or exotoxins) that can directly injure cells
resulting in organ dysfunction. Thus, higher-order organisms
deploy a robust immune system comprised of two separate
arms: the innate immune system that provides relatively im-
mediate and non-specific immunity and the adaptive immune
system that provides the system’s “memory” arm. While this
dichotomization is simplistic conceptually, in fact the two
arms are integrally linked.
The innate immune system is responsible for initial pathogen
recognition and subsequent mounting of an effector response.
To fulfill the responsibility of surveying the host environment
for foreign pathogens, cells of the innate immune system (e.g.,
monocytes, macrophages, neutrophils, natural killer [NK] cells)
have acquired a series of cell-surface receptors called pattern-
recognition receptors (PRRs) that detect molecular patterns
foreign to the host [8]. These receptors are capable of recogniz-
ing conserved molecular moieties expressed by various patho-
gens termed “microbial- or pathogen-associated molecular pat-
terns” (MAMPs or PAMPs) that include various components of
invading pathogens, such as lipopolysaccharide (LPS) from
Gram-negative bacteria. Among the most important family of
PRR’s are the Toll-like receptors (TLR) that possess specificity
for the variety of pathogens that infect humans (Table 3)
(reviewed in [8]). In addition to the TLRs, other intracellular
PRRs exist including nucleotide-binding oligomerization do-
main (NOD)-like receptors (NLRs) that detect peptidoglycan of
Gram-positive bacteria in the cytosol and retinoic-acid-
inducible protein (RIG)-like receptors (RLRs) that detect viral
double-stranded RNA to induce type I interferon production
[9]. Engagement of PRR’s by MAMPs triggers an effector
response mediated by consequent activation of cells of the
innate immune system that drives expression of numerous
inflammatorymediators. It is worth noting that while pathogens
trigger immune activation, it is well understood that endoge-
nous molecules released upon tissue damage and/or cellular
disruption (e.g., high mobility group protein B1 [HMGB1],
S100 proteins, and heat shock proteins) are similarly capable
of activating the immune system through PRRs resulting in a
systemic response indistinguishable from sepsis (reviewed in
[10]). Such molecules are referred to as “damage-associated
molecular patterns” (so-called DAMPs) or alarmins that can
trigger systemic release of immune mediators [11]. Regardless
of the trigger, these circulating mediators are responsible for
activation and recruitment of cells targeting localized pathogen
killing; however, when their expression is dysregulated, sys-
temic spillover can affect numerous physiologic perturbations
that are the hallmark of sepsis.
One of the earliest identified cytokines causally linked to
sepsis is tumor necrosis factor-α (TNF). TNF drives adhesion
molecule and chemokine expression to facilitate leukocyte-
endothelial cell adhesion and cause endothelial barrier dysfunc-
tion (reviewed in [12]). TNF upregulates tissue factor and in-
hibits protein C to contribute to a pathologic pro-coagulant state
within the microvasculature and also mediates pathologic vaso-
dilation, myocardial depression and afferent renal artery vasodi-
lation by inducing nitric oxide (NO) synthase andNOproduction
to potentially reduce transglomerular pressure [13]. A related
cytokine, interleukin (IL)-1β elicits fever, hypotension and leu-
kocytic infiltration to numerous organs in animal models. IL-1β
also activates monocytes and increases adhesion molecule ex-
pression as well as tissue factor expression while inhibiting
thrombomodulin secretion. These effects contribute to a
procoagulant state in sepsis that leads to disseminated microvas-
cular thrombosis and thus, end-organ ischemia—including with-
in the kidney. There are several other important proinflammatory
cytokines and mediators that contribute to sepsis pathology that
are beyond the scope of this review [14, 15]. It is important to
recognize that while inflammation is necessary for pathogen
clearance, this immune response must ultimately be contained
in a controlled manner in order to reestablish homeostasis and
avoid cellular and tissue damage. This function is served by a
counter-regulatory immune response.
Table 3 Pathogen/microbial-associated molecular patterns (P/MAMP)

















CpG DNA motifs TLR9 Bacteria,
DNA
Profilin-like proteins TLR10
PRR, pattern recognition receptors
a Synthetic triacylated lipopeptide
bHeterodimerizes with TLR1, TLR2
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To maintain immune homeostasis following infection, the
proinflammatory response must be down-regulated. This
function is mediated by a counter-regulatory, anti-
inflammatory response ‘syndrome’ (so-called “CARS”) that
results from expression of various endogenous cytokine an-
tagonists, including soluble TNF receptors that bind to and
inactivate TNF, interleukin-1 receptor antagonist (IL-1Ra) that
blocks IL-1 effect and other anti-inflammatory cytokines,
such as IL-10 and transforming growth factor (TGF)-β. IL-
10 directly inhibits expression of cytokines known to contrib-
ute to sepsis and also increases expression of other anti-
inflammatory molecules such as IL-1Ra and soluble TNF
receptors (reviewed in [16]). Importantly, it has become clear
that just as with the pro-inflammatory response, the compen-
satory response can also be dysregulated [17]. When
prolonged, this dysregulation may impair pathogen clearance
via over-suppression of the immune response and impact
mortality from sepsis. Data from gene expression profiling
of children dying from septic shock have demonstrated sig-
nificant repression of genes associated with critical immune
functions: antigen presentation, T-cell and B-cell activation
and natural killer cell function [18]. In addition to reduced
gene expression, functional defects in several immune cell
types characterized by impaired activation of monocytes, T-
cells and neutrophils by pathogens have been described in the
later phase of sepsis [19, 20]. Post-mortem analysis has found
that nearly 80 % of septic adults had evidence of unresolved
infection [21], and the common occurrence of nosocomial
sepsis, often associated with less virulent, opportunistic infec-
tions as well as the reactivation of latent viruses all imply
immune dysfunction in the septic host. Given these observa-
tions, it is increasingly suggested that monitoring immune
function and appropriate, targeted immune adjuvant therapies
to enhance immune cell function may hold much more sig-
nificant promise as a therapeutic approach [22]. As early
resuscitative efforts have improved the survival from acute
sepsis, it is argued that this ‘late’ phenomenon is responsible
for the trend towards later deaths among both adults and
children succumbing to sepsis. Given the risks related to
immune dysfunction in the patient with sepsis, strict attention
to protocols that reduce the occurrence of nosocomial infec-
tions (e.g., catheter-associated blood stream infections and
ventilator-associated pneumonia) is imperative, as preventing
a sepsis trigger may be more important, and achievable, than
eradicating an infection once established (see Sepsis preven-
tion strategies below).
Insights as to how sepsis induces acute kidney injury
(AKI)
Within the context of sepsis pathology, a primary question for
the pediatric nephrologist is how sepsis induces AKI. The
logical presumption is that impaired hemodynamics and hy-
potension lead to an under-perfused state of the kidneys with
consequent injury. However, both animal and human studies
in sepsis have indicated that maintaining systemic pressure
does not necessarily prevent AKI, and that decreases in renal
blood flow and glomerular filtration rate can be seen follow-
ing injections of LPS even when there is no change in sys-
temic blood pressure [23, 24]. This has suggested that the
degree of organ dysfunction in humans with sepsis correlates
with alterations in microvascular circulation [25–27]. In order
to further elucidate mechanistic causes of sepsis-induced AKI,
investigators have utilized a variety of experimental models
ranging from small to large animal models.
While not necessarily replicating all the physiologic man-
ifestations of human sepsis, murine models using pathogen-
associated challenges (e.g., LPS) do produce AKI and have
been used to study the role of MAMP-induced inflammatory
responses in causing renal injury [28]. Consistent with the
cascade described above, this work linked the generation of
LPS-induced cytokines (e.g., TNF) to consequent induction of
nitric oxide (NO) synthesis [29]. Generation of NO leads to
increased reactive nitrogen species and activation of caspases
known to contribute to programmed cell death, or apoptosis
[30]. Studies have further confirmed the role of reactive nitro-
gen species and apoptosis in mouse models of sepsis-induced
AKI. For example, Lee et al. observed increased renal tubular
cell apoptosis in a mouse model of sepsis, and found that
inhibition of caspase-3 (a critical mediator of apoptosis) pre-
served kidney function [31]. Mayeux and colleagues have
similarly shown that agents that scavenge or inhibit reactive
oxygen and reactive nitrogen species rescue renal peritubular
capillary blood flow and decrease renal tubular cell injury [32,
33]. This work concluded that cytokine-mediated endothelial
injury and capillary dysfunction along with vasodilation are
important factors in the development of AKI [28–30].
Interestingly, in the setting of systemic vasodilation in sepsis,
activation of the renin–angiotensin–vasopressin system may
cause paradoxical renal vasoconstriction [34], stressing the
importance of using alternative models to obtain a better
understanding as to how endothelial stress in sepsis impacts
peritubular capillary dysfunction that may reveal novel thera-
peutic approaches [34].
Because several limitations exist in the translation of findings
from murine models to humans, and vasculature cannot readily
be cannulated in mice, researchers have employed large animal
models involving intravenous infusion of live pathogens (e.g.,
Pseudomonas aeruginosa, E. coli) or autologous fecal peritoni-
tis, in order to discern the physiologic renal responses associated
with the consequent development of AKI [35, 36]. These
models have demonstrated similar variability in the incidence
of sepsis-induced AKI (40–62 %) as is typically observed in
older adult cohorts (∼50 % incidence), suggesting they may
reasonably reflect human pathophysiology. Benes et al. recently
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observed that despite being subjected to similar degrees of
pathogen challenge, showing comparative hemodynamic re-
sponses and receiving uniform fluid and vasoactive support,
the only animals (pigs) that developed AKI were those that
demonstrated progressive increases in renal vascular resistance
which did not correlate with systemic hemodynamics [35]. In
fact, consistent with the hypothesized role of inflammation
driving renal injury, those animals developing AKI demonstrat-
ed an earlier and more robust inflammatory response (measured
by circulating TNF-α and IL-6 levels) and higher oxidative
stress (measured by thiobarbituric acid reactive species
[TBARS]) [35]. Such studies highlight the likely failure of
focusing only on management of systemic hemodynamics to
ameliorate AKI, however, in the absence of advances in mon-
itoring the capability of organ-specific perfusion, the bedside
clinician is left with this ‘crude’ measurement.
Despite the insight gained from these studies, additional
questions were raised as a result of observations from a sheep
model of sepsis-induced AKI [36]. In this model, infusion of
E. coli over a 48-h interval, followed by antibiotic administra-
tion and recovery (for an additional 48 h) induced a
hyperdynamic, vasodilatory model of sepsis. These investiga-
tors observed renal vasodilation and subsequent increased
renal blood flow in the early sepsis phase, but relative renal
vasoconstriction and reduction in renal blood flow as the
animal recovered, providing further evidence for the role of
renovascular resistance (RVR) in inducing AKI and demon-
strating the causative mechanism to be much more complex
than hypoperfusion due to decreased cardiac output and hy-
potension. Sepsis-induced renal microvascular alterations trig-
gered by vasoconstriction, capillary leak with consequent
tissue edema, endothelial dysfunction with microthrombosis
(see below), and/or elevated intra-abdominal pressure might
all contribute to increased RVR. This may also explain the
increased incidence of AKI in adults with sepsis who require
systemic vasopressors (e.g., norepinephrine and/or vasopres-
sin) to maintain adequate systemic blood pressure.
With all these models it remained incompletely understood
as to whether systemic and/or local (kidney produced) cyto-
kines were predominantly responsible for triggering AKI.
‘Traditional’ thinking had surmised that TLR-dependent acti-
vation of circulating leukocytes led to their activation and
consequent systemic cytokine production that either directly
or indirectly contributed to renal injury. However, mammali-
an renal tubular cells constitutively express a number of
TLRs (1, -2, -3, -4, and −6) [37] and in vitro stimulation
with LPS can increase their expression of both inflamma-
tory mediators, as well as TLR’s (2, 3, and 4) themselves
[38]. These data raise the possibility that tubular cell TLR’s
might locally direct the recruitment of interstitial leukocytes
into the kidney with consequent tubular injury during system-
ic sepsis (reviewed in [38]). Delineating this was testable by
an elegant study of LPS-induced AKI utilizing transgenic
mice deficient in TLR4 expression. These mice, which lack
a systemic TNF response to LPS, were found to be resistant to
endotoxin-induced AKI [28]. However, using cross transplan-
tation, these investigators showed that while TLR4-deficient
recipients of wild-type kidneys developed minimal LPS-
induced AKI, wild-type recipients of a TLR4-deficient kidney
did in fact develop severe acute renal injury after endotoxin
[28]. Thus, these data implicate the systemic inflammatory
response during sepsis as the primary driver of AKI (and very
likely other organs) in sepsis. Interestingly, converse findings
were obtained when the specific role of TNF was examined
using TNF receptor-1 (TNFR1)-deficient mice [29]. In these
studies, TNFR1 null mice were resistant to LPS-induced AKI
with less renal inflammation and reduced apoptosis of tubular
cells providing support for a role of cytokines in causing
tubular cell apoptosis as a putative mechanism for sepsis-
induced AKI [39, 40]. Furthermore, in contrast to TLR4 null
mice, TNF receptor (TNFR)-positive kidneys that were
transplanted into TNFR null mice did show evidence of local
injury and AKI, whereas the TNFR null kidneys transplanted
into wild type mice did not. These data suggest that TNF plays
a very direct and local role in LPS-triggered AKI [29], though
exactly how remains incompletely known.
Though there is ample evidence that systemic inflamma-
tion in sepsis is a key driver of end-organ dysfunction, there is
an inconsistent association of AKI with sepsis-induced alter-
ations in systemic hemodynamics, which suggests other
mechanisms may be at play. As mentioned earlier, the “cyto-
kine storm” of proinflammation concomitantly activates the
coagulation cascade and impairs fibrinolysis, driving a func-
tional hypercoagulable state that can ultimately lead to dis-
seminated microvascular thrombosis [41]. An early link be-
tween inflammation and activation of the coagulation cascade
in contributing to organ dysfunction was supported by autop-
sy findings of clots comprised of neutrophils, platelets and
fibrin in the microcirculation of patients dying of sepsis-
induced multiple organ failure likely as a result of ischemia
[42]. This pathophysiology is often characterized by platelet
consumption with subsequent thrombocytopenia so that clini-
cian investigators refer to this cause of multiple organ dys-
function as thrombocytopenia-associated multiple organ fail-
ure (TAMOF) [43]. TAMOF is characterized as a thrombotic
microangiopathic process, similar to that described in throm-
botic thrombocytopenic purpura (TTP), which is character-
ized by decreased ADAMTS13 protease activity causing ac-
cumulation of large, multimeric vonWillebrand Factor (vWF)
[44]. As a pro-thrombogenic protein released into the circula-
tion by the vascular endothelium and platelets, vWF provides
hemostatic function at sites of vascular injury [45]. In the
normal state, circulating proteases, notably ADAMTS13, de-
grade vWF into smaller multimers thereby reducing the
thrombogenic propensity of vWF; however, in sepsis this
homeostatic function may go awry. For example, in some
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cases of severe sepsis, attenuation in the release of
ADAMTS13 results in the formation of large vWF multimers
causing disseminated microvascular thrombosis and organ
failure [45]. This observation would suggest that plasma ex-
change, by clearing large vWF multimers and replacing
ADAMTS13 with fresh plasma, may improve organ
dysfunction/AKI by diminishing circulating vWF multimers.
These results have important implications for the use of ex-
tracorporeal therapies, notably continuous renal replacement
therapy combined with plasmapheresis/exchange in treating
sepsis and sepsis-induced AKI—particularly in the specific
setting of TAMOF.
In summary, sepsis-induced AKI appears to be driven by
release of systemic, rather than local, inflammatory cytokines.
However, the contribution of systemic hemodynamic changes
appears less important than local changes in renal perfusion
mediated by imbalance of afferent and efferent vasodilation/
contraction—the cause(s) of which remain to be fully eluci-
dated. Tubular cell apoptosis and microvascular thrombosis,
both driven by systemic release of proinflammatory cytokines,
may also be important contributing factors. It remains imper-
ative to better understand this multifactorial pathology since
the health care burden of sepsis-induced AKI as reflected by
the epidemiology is substantial.
Epidemiology of sepsis-induced AKI
Sepsis is a common reason for admission to the pediatric
intensive care unit (ICU) and carries significant mortality,
morbidity, and cost to the health care system [2]. In the past,
epidemiological studies of pediatric sepsis were hampered by
non-standard definitions and a similar deficiency has impaired
accurate reporting of the incidence of pediatric AKI. Noting
over 30 definitions of AKI in published literature, the Acute
Dialysis Quality Initiative Group proposed the Risk, Injury,
Failure, Loss, End-Stage Kidney Disease (RIFLE) system to
standardize definitions (Table 4) [46]. These criteria were
modified for pediatrics to yield the pRIFLE score that has
been proposed for prospective studies examining AKI in
children [47]. Further modifications of RIFLE are reflected
in the Acute Kidney International Network scoring system
and in the Kidney Disease Improving Global Outcomes
(KDIGO) clinical practice guideline for AKI, though these
have yet to be validated in pediatrics [48, 49]. Early studies
were confounded by non-standard definitions for sepsis,
AKI, or both; nevertheless, these historical data provide
general insight into the burden and impact from
sepsis-induced AKI. With the establishment of a consis-
tent scoring system capable of better defining the inci-
dence of AKI in children, studies clearly show that
sepsis is not only one of the most common etiologies
for AKI, but that the combination of AKI and sepsis
results in worse outcomes than either entity alone.
Early studies not using standardized AKI definitions
In a retrospective review of case records of hospitalized chil-
dren over 22 years in a university hospital in Thailand, sepsis
was noted to be among the major causes of AKI (21.4 %) [50].
Mortality associated with AKI from all causes was 41.5 %,
while mortality in those with sepsis-induced AKI was 66.2 %
with an odds ratio for mortality of >17 if sepsis was the cause
of AKI [50]. In a retrospective, single-center study in
Lithuania of children diagnosed with AKI, sepsis was the
primary cause in 21.8 % of patients from 1998–2008 [51].
In this report, AKI was defined as urine output <1 cc/kg/h for
6 h, rise of serum creatinine by 26.4μmol/l (0.3 mg/dl), or an
increase in creatinine to >150–200 % of prior baseline. In a
retrospective review of children in septic shock, Plotz et al.
reported mortality rates were significantly higher in patients
with AKI (defined as need for RRT) (57.1 %) versus those
without AKI (6.7 %) [52]. Subjects were defined as having
septic shock if they remained hypotensive despite fluid resus-
citation and dopamine and required any additional vasopres-
sor agent (most commonly norepinephrine). These epidemio-
logic findings (sepsis triggering ∼1/4 of AKI) and mortality
rates from sepsis and AKI being in the range of 30–40%, have
been described in a variety of other retrospective studies
[53–55]. In the only prospective study performed before
the era of more precise definitions, sepsis was identified
as an important (9.1 %) but not the major cause of AKI
observed in children admitted to the PICU with other
etiologies including hemolytic-uremic syndrome
(18.2 %), hematology-oncology disease (18.2 %), and
post-cardiac surgery (11.4 %) [56]. Mortality in those
with AKI was 27.3 % versus 2.4 % in those who did
not have AKI, though the impact of sepsis on mortality
in this cohort was not specifically reported. Taken to-
gether, these studies clearly establish sepsis is an impor-
tant and, as suggested below, increasing cause of AKI.
Studies using standard AKI definitions
While perhaps still controversial insofar as their prognostic
value, several recent standardized definitions of AKI have
been derived and described for use in children: pRIFLE, the
Acute Kidney Injury Network (AKIN) Staging Criteria, and
the KDIGO clinical practice guideline for AKI (see Table 4)
[47–49]. The publication and use of these definitions has
enabled a more accurate delineation of the association of
sepsis with the development of AKI. AKI in hospitalized
children using both standard definitions (for sepsis and AKI)
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has consistently been associated with poor short-term out-
comes (notably, mortality and length of stay) [2, 47, 48, 50].
A retrospective, single-center study of PICU patients requir-
ing mechanical ventilation for >4 days utilized the pRIFLE
criteria for identifying the incidence of AKI in this cohort [57].
Sepsis was significantly more prevalent in those with AKI
(20 %) versus those without AKI (5 %) and mortality was
five-times higher in those with AKI (25 %) versus those
without (5 %). In the initial validation study of pRIFLE, 150
children admitted to the PICU were prospectively enrolled
over a 12-month period and 82 % developed AKI as deter-
mined using pRIFLE criteria [47]. The remaining 18% served
as controls for comparison. Between these two cohorts, there
were no significant differences insofar as PICU admission
diagnoses, including SIRS/sepsis/septic shock (18.5 % in
control group, 26.8 % in AKI group; p value >0.05).
However, these data were collected on a general PICU popu-
lation, and studies in more severely ill cohorts amplify the
incidence and impact of AKI in sepsis.
For example, a retrospective study of burn patients in the
PICU applied the pRIFLE criteria and found the incidence of
AKI to be 45.5 % and those with AKI developed sepsis during
their PICU stay more frequently than those without (38.4
versus 19.8 %) [58]. In addition, 82 % of patients who devel-
oped AKI late (after 5 post-burn days) had documented epi-
sodes of sepsis as compared to only 19 % of those who had
earlier occurrence of AKI presumed to be related to acute,
burn-related hemodynamic compromise. A prospective multi-
center study in Turkey used standardized definitions for AKI
(pRIFLE) and sepsis to identify the association of AKI with
sepsis [59]. Sepsis was the cause of AKI in 18.2 % of patients,
exceeded only by hypoxic-ischemic injury (28 %). Septic
shock was present in nearly a quarter of the children with
sepsis and multivariate logistic regression analysis indicated
that the presence of septic shock and AKI predicted mortality
in patients >1 month old [59]. Overall, there has been a paucity
of similar large, cohort studies that have combined the use of
standard definitions for both sepsis and AKI, thus the true
incidence and interaction of sepsis and AKI remains incom-
pletely defined in pediatrics. Nevertheless, these few studies
indicate that the presence of sepsis is a risk factor for develop-
ment of severe AKI and a significant predictor of mortality.
Table 4 Acute kidney injury classification systems




RIFLE R (risk) ≥1.5-fold Cr increase or
GFR decrease≥25 %
<0.5 ml/kg/h for 6 h
I (injury) ≥2-fold Cr increase or
GFR decrease≥50 %
<0.5 ml/kg/h for 12 h
F (failure) ≥3-fold Cr increase or
Cr >4.0 mg/dl
<0.3 ml/kg/h or anuria for 12 h
L (loss) Persistent failure >4 wk
E (end stage) Persistent failure >3 mo
pRIFLE R (risk) GFR decrease≥25 % <0.5 ml/kg/h for 6 h
I (injury) GFR decrease≥50 % <0.5 ml/kg/h for 12 h
F (failure) GFR decrease≥75 % or
eGFR<35 ml/min/1.73 m2
<0.3 ml/kg/h or anuria for 12 h
L (loss) Persistent failure >4 wk
E (end stage) Persistent failure >3 mo
AKIN Stage 1 ≥ 0.3 mg/dl Cr increase or
150–200 % increase above baseline
<0.5 ml/kg/h for 6 h
Stage 2 Cr increase of 200–300 % of baseline <0.5 ml/kg/h for 12 h
Stage 3 Cr increase≥300 % of baseline or
≥4.0 mg/dl with an acute increase of 0.5 mg/dl
<0.3 ml/kg/h or anuria for 12 h




Stage 2 Cr increase of 2.0–2.9 times baseline <0.5 ml/kg/h for
≥12 h




initiation of renal replacement therapy
or
eGFR <35 ml/min per 1.73 m2 in patients <18 years
<0.3 ml/kg/h for
≥24 h or
anuria for ≥12 h
AKIN, Acute Kidney Injury Network; KDIGO, Kidney Disease Improving Global Outcome; eGFR, estimated glomerular filtration rate
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While many studies associate sepsis with AKI, causality has
been much more difficult to prove. Multiple factors (including
sepsis) may result in AKI, and differentiating the contribution
of any one insult is challenging. Therefore, the predictive
capability of renal-specific scores may be insufficient such that
an alternative approach that incorporates confounding factors
has been proposed [60]. Basu et al. suggested such a method-
ology to improve prediction of AKI using a concept described
as “renal angina” to enhance AKI biomarker efficiency [60,
61]. This proposed clinical guideline integrates baseline, con-
textual and clinical evidence of kidney injury such that the “risk
of AKI” multiplied by the “evidence of AKI” provides a so-
called renal angina threshold—much like the presence of myo-
cardial infarction risk factors in the presence of chest pain
triggers a troponin determination. These investigators provided
a diagnostic framework on the basis of risk stratifications by
factoring the clinical state and evidence of renal dysfunction
such that as the clinical risks increase, the need for evidence of
renal dysfunction decreases (see Table 5) [61]. This approach
was recently tested in a multi-center retrospective cohort and
found to be superior to existing AKI classification systems
based simply on serum creatinine and urine output [62].
Whether this approach can be applied in future prospective
studies to better predict sepsis-induced AKI and its impact in
children remains to be seen. However, such efforts may help
earlier identification of optimal therapies to ameliorate the
impact of sepsis on AKI and overall clinical outcomes.
Impact of kidney injury/failure on sepsis risk
To this point, we have focused on the epidemiology and
pathophysiology of sepsis and its effect on causing AKI.
However, it is imperative for the pediatric nephrology
community to recognize the potential impact of AKI (and
chronic kidney injury/failure) on predisposing the host to
sepsis. Very few studies have examined the incidence and
potential mechanisms associated with the development of
sepsis after established AKI in children. In the largest obser-
vational study to date 618 adult ICU patients with AKI (n=
391; 64 % of whom required dialysis) were prospectively
followed within the five-center Program to Improve Care in
Acute Renal Disease (PICARD) [63]. As one would expect,
sepsis preceded the onset of AKI in a large number (n=174;
28 %); however, 243 patients (40 %) developed sepsis a
median of 5 days after the onset of AKI. Interestingly, this
percentage was similar to that reported from a smaller, single-
center study of contrast-induced AKI in which 45 % of
patients (21/47) developed sepsis after AKI [64]. One would
speculate that the invasive nature of central venous or perito-
neal catheters and institution of dialytic therapies would pre-
dispose this cohort to developing sepsis post-AKI and in fact,
the need for dialysis was identified as an independent risk
factor [64]. Other independent risk factors for the develop-
ment of sepsis post-AKI included oliguria ≥3 days, higher
percentage of days with fluid overload post-AKI, invasive
non-surgical procedures post-AKI and high severity of illness
(SOFA) scores. Such observations raise the need for further
understanding the potential mechanisms by which renal dys-
function impacts the immune system.
The concept that AKI may impact the immune system to
consequently predispose the host to infectious complications
has been suggested by the observation that infections are
among the most common causes of death in patients with
renal failure [65]. This suggests that an unidentified compo-
nent of renal injury/failure (e.g., uremia) contributes to an
immunocompromised state; however, given that severe sepsis
is associated with a late phase of immune dysfunction, it is
difficult to know which pathophysiologic process may drive
this alteration. In trying to identify relevant mechanisms, more
work has been done in patients with end-stage renal disease
(ESRD) who show a decreased ability to clear bacterial, viral
and fungal infections, and show impaired responses to vac-
cines (e.g., Hepatitis B) and decreased delayed-type hypersen-
sitivity (DTH) (both of which require T-cell-dependent anti-
gen responses) [66]. This may be relevant to sepsis biology as
a similar finding of repressed gene expression in T-cell sig-
naling was observed in pediatric septic shock [67]. In contrast
to T-cell function, patients with ESRD appear to have intact B-
cell function with normal levels of total immunoglobulins (in
the absence of proteinuria) and intact vaccine responses to T-
cell-independent polysaccharide antigens [66, 68].
Investigators have tried to identify the cellular immune
alterations that result from renal dysfunction/failure; however,
the results are inconsistent. This is likely related to small
cohort sizes, heterogeneity of precipitating causes of the renal
failure and variable host genetics. Also, the majority of the
Table 5 Pediatric renal angina criteria*
Risk category Renal angina threshold
Moderate risk
• PICU patient • Doubling of SCr, OR
• eCrCl decrease >50 %, OR
• Fluid overload >15 %
High risk
• Acute, decompensated heart failure • Serum Cr increase >0.3 mg/dl,
OR
• eCrCl decrease 25–50 %,
• Fluid overload >10 %
• Stem-cell transplant
Very high risk
• Receiving mechanical ventilation
and one or more vasoactive
medications
• Any serum Cr increase
• eCrCl decrease >25 %,
• Fluid overload >5 %
PICU, Pediatric Intensive Care Unit
*Adapted from references [61, 62], used with permission
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samples have been obtained from patients already on dialysis,
making it difficult, if not impossible to distinguish those
effects resulting from uremia versus the dialysis modality
itself. In spite of these confounders, multiple alterations to
neutrophil function have been described including decreased
chemotaxis, impaired phagocytosis, decreased oxidative
burst, and decreased intracellular killing. However, it is un-
clear how many of these defects were related to the now
historical use of bioincompatible cuprophane membranes
[69], as recent studies suggest neutrophil phagocytosis and
reactive oxygen species production may in fact be preserved
in renal failure [70]. With regards to circulating monocytes,
key drivers of the sepsis response, numerous studies on adult
dialysis patients have demonstrated monocyte activation in-
cluding upregulation of integrin expression and increased pro-
inflammatory cytokine production [71]. Based on these re-
ports, it is widely believed that uremia’s affect on monocytes
may contribute to a chronic inflammatory state with increased
oxidative stress that in turn contributes to the increased car-
diovascular disease in ESRD [72].
In addition to alterations in the cells of the innate immune
system, studies of lymphocytes (adaptive immune system)
isolated from ESRD patients have shown increased markers
of basal activation and apoptosis, but decreased proliferative
responses to mitogens [73, 74]. This altered response is similar
to lymphocyte dysfunction that has been described in the later
phase of pediatric sepsis which is associated with increased risk
of both infection and mortality [75]. Additional studies have
looked at the impact of ESRD on CD4+ T-cell differentiation
into TH1 and TH2 subtypes, as the balance between these
subtypes impacts the ability of the immune system to combat
infectious challenges. Data regarding the impact of uremia on
T-cell function comes from examination of intracellular cyto-
kine staining of freshly isolated CD4+ T-cells from ESRD
patients. These studies show that uremic patients not on dialysis
have increased IL-4- and IL-10-positive T-cells, suggesting a
shift towards the immune modulating, TH2 phenotype [76].
Given the inherent limitations of studies of circulating leuko-
cytes, it is clear that there is still much to discover about how
renal failure and uremia impact immune function, which re-
mains incompletely understood. Given the predilection for
developing infections in the chronic renal failure cohort, it is
important to adopt management strategies that prevent infec-
tions so that sepsis is never established in this at-risk group. To
that end, centers should employ strategies to reduce infectious
complications (e.g., catheter-associated blood stream infec-
tions) in cohorts requiring acute and chronic dialysis.
Sepsis prevention strategies
Recognizing the increased sepsis risk in the cohort of patients
with either ESRD or, as noted above, with AKI, our center
established a dialysis-specific catheter associated-blood
stream infection (CA-BSI) eradication initiative. A multidis-
ciplinary team of nephrologists, dialysis/apheresis nurses, di-
alysis nurse manager, infection control practitioner, a physi-
cian assistant specializing in dialysis catheter insertions, and
hospital administration reviewed current best practices for
accessing and maintaining dialysis catheters, including rec-
ommendations from the Centers for Disease Control (CDC),
Centers for Medicare and Medicaid Services (CMS), and the
National Association of Children’s Hospitals and Related
Institutions (NACHRI; now CHA). A standard procedure for
accessing dialysis catheters and maintaining the catheter and
its exit site was developed utilizing evidence-based, best prac-
tices. An education module demonstrating the accessing pro-
cedure was developed by the team who then performed audits
to identify breaches in the standardized practice. The infor-
mation garnered from these audits was used to develop a final
checklist of ten critical steps to incorporate into a maintenance
bundle focusing on practices that needed to be done at every
instance of catheter accessing and exit site dressing changes
(Fig. 1). Patients and families also received education from the
dialysis/apheresis nurses regarding the updated procedure for
accessing and maintaining dialysis catheters.
After implementation of the checklist, compliance was
audited over the next 18 months such that each pediatric
dialysis patient with a catheter had both self- and anonymous-
ly observed audits completed at each encounter and results
were reviewed monthly by the eradication team and unit
nurses. Areas with low compliance were addressed with staff
to identify operational causes for non-compliance and to re-
design workflow. In striving toward a 100 % compliance rate,
a prominent, visual charting of the metric “Days since last
CA-BSI” was displayed in the unit. Most importantly, over
time higher compliance rates translated to a statistically sig-
nificant decrease in the number of CA-BSI’s. In the event a
CA-BSI occurred, root cause analysis was performed to iden-
tify potential barriers to bundle compliance, disseminate les-
sons learned and refine preventable measures. Given the chal-
lenges inherent to managing children with sepsis, this ap-
proach and other related efforts (e.g., antimicrobial lock solu-
tions) aimed at preventing sepsis events by eliminating com-
mon triggers are not trivial achievements [77, 78]. Indeed, the
KDIGO group’s AKI guidelines devote a chapter on vascular
access for RRT in AKI with special attention towards decreas-
ing the rate of catheter-related infections [79].
Use of renal replacement therapy to modulate
the inflammatory response
While prevention of sepsis remains an ideal goal, sepsis will
remain a major cause of morbidity and mortality in pediatrics.
Due to vascular “leak” from endothelial barrier dysfunction,
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CATHETER ENTRY (Connecting/Disconnecting)
(Circle Yes – If done 100% of the time; Circle No – If done < 100% of the 
time)
Y N Hand hygiene (wash or sanitizer) done before each entry
Y N Hand hygiene (wash or sanitizer) done after each entry
Y N All supplies were gathered placed by patient prior to starting 
the procedure (to prevent interruption of procedure leading to 
potential contaminations)
Y N Machine preparation complete prior to starting procedure 
(Includes priming, setting treatment parameters, and clamping 
blood lines)
Y N Alcohol swab used to remove cap from catheter
Y N “Scrub the Hub” / 15 second scrub done prior to each entry








 Pediatric  
 Acute  











If N breach was: Connecting Disconnecting
Reversing Line
Y N Sterile gauze or drape used under the permanent catheter for 
each entry
Y N Maintained a separation of clean hand and dirty hand during 
the procedure
Y N Gloves used prior to each entry
Y N NA Gown, mask/shield or goggles used prior to each entry
Fig. 1 Dialysis catheter CA-BSI checklist. *One sheet for each patient treated on the day of the audit*. Completed forms go in CA-BSI envelope at
nurses’ station. Please share comments/suggestions/questions on the back of this form
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possibly contributing to and/or in combination with AKI [80],
it is common that patients with sepsis develop a fluid-overload
state that has been suggested to impact this mortality [81, 82].
As a result, there is a frequent indication for instituting renal
replacement therapy to aid in the management of oliguria and
consequent volume overload, as well as metabolic acidosis,
uremia (notably in the surgical patient where platelet
dysfunction/bleeding is an important consideration), mainte-
nance of electrolyte homeostasis and the ability to provide
nutrition. Given the typical tenuous hemodynamics of patients
with sepsis, continuous renal replacement therapy (CRRT),
most commonly in the form of continuous venovenous
hemofiltration (CVVH) +/− hemodialysis (HD), is the stan-
dard modality used. Perhaps the most controversial decision
of applying CRRT is the timing of its initiation. Herein, we do
not review the data regarding the impact of fluid overload and
possible benefits of earlier initiation of RRT as this has been
reviewed in a number of recent reports [83, 84]. Instead, we
highlight potential theoretical advantages to utilizing
RRT to address the hypothesis that CRRT may provide
a beneficial effect on modulation of the immune system
in sepsis-induced AKI.
Since the introduction of CRRT into ICU practice, physi-
cians involved in managing AKI patients have considered a
paradigm whereby hemofiltration may clear the blood of
“bad” pro-inflammatory mediators. First, it is important to
acknowledge that it is inaccurate to label any given mediator
as “good” or “bad” as molecules possess numerous functions
that at one point in time may be beneficial (e.g., TNF-
mediated neutrophil activation to kill a pathogen) or harmful
(e.g., TNF-mediated lymphocyte apoptosis leading to immune
paralysis). Second, as reviewed above, there is increasing
evidence that both pro- and anti-inflammatory mediators can
be equally dysregulated and imbalanced in the many critical
septic patients—often simultaneously. Thus, it is imperative
that what is designed to be a “functional” response to patho-
gen invasion of the host can be effectively regulated so that
immune homeostasis can be preserved. The concept of utiliz-
ing CRRT modalities to not simply remove mediators from
the circulation, but rather reduce and balance them to achieve
homeostasis has been described as the so-called, “peak-con-
centration” hypothesis espoused by Ronco and colleagues
[85]. The basis of this hypothesis is the concept that reducing
the peaks of circulating mediators through use of extracorpo-
real filtration methodologies can substantially reduce their
pathophysiologic impact. In testing this hypothesis over the
past decade, several considerations in terms of timing, dosing
and modality have been considered, but identifying distinct,
effective approaches has proved challenging.
With use of CRRT, three mechanisms exist for mediator
removal and consequent “blood purification”: convection,
diffusion, and/or adsorption [86]. As a result, clinician-
investigators have attempted to maximize these various ap-
proaches using CVVH with or without dialysis in order to
determine if they could improve clinical outcomes in sepsis.
Given that a higher dosing of CVVH should be associated
with greater convective clearance of mediators, studies pro-
spectively examined this treatment effect. Early promising
results in adults were obtained by Ronco et al. who tested
CVVH doses of 20, 35 and 45 ml/kg/h in a 425 adult ICU
DRESSSING CARE
Y N Dressing change procedure completed
If N Audit complete
If Y Continue Audit
Reason Why: ≥ 7days (transparent) or ≥ 2days (gauze)
Dressing soiled/damp/loose
Dressing not dated (Uncertain when dressing last changed) 
Procedure:
Y N CHG 30 sec. scrub + 30 sec. air dry done with dressing 
change
Y N Biopatch placed
Fig. 1 (continued)
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cohort with AKI, and observed improved survival in the
higher-dose groups (35 and 45 ml/kg/h) as compared to the
20ml/kg/h group [87]. However, because only∼15% of those
enrolled had sepsis it was not possible to delineate a specific
potential benefit in this minority of the cohort. Thus, in a
subsequent study of over 200 AKI patients with over half
(60 %) admitted with sepsis, higher-dose (42 ml/kg/h) versus
“standard” CVVHD (24 ml/kg/h) showed improved survival
giving credence to the possibility that higher “dosing” of
hemofiltration—possibly due to greater mediator clear-
ance—may have led to improved outcomes [88]. However,
two recent trials that enrolled a substantially higher proportion
of adults with sepsis (>60 %) did not support this conclusion
[89, 90]. These observations in adults may not be relevant for
pediatricians since with infant and child sizes with consequent
estimated blood volume and achievable blood flow rates, even
higher “dosing” of CVVHD can be delivered in children such
that the studies examining even higher volume hemofiltration
may be more directly relevant to determining the benefit of
such an approach. In fact, a small trial of 33 adult patients with
septic shock randomized to either 35 ml/kg/h versus 100 ml/
kg/h over a 6-h period, demonstrated significantly lower cir-
culating IL-6 levels consistent with the ‘peak concentration’
hypothesis; however, the study was too small to determine the
influence on mortality [91]. Unfortunately, though the peak
concentration hypothesis seems logical, very few studies in
pediatric patients with sepsis-induced AKI have examined the
impact of high-volume hemofiltration in sepsis-induced AKI.
Because a beneficial effect of high-volume hemofiltration
has not been definitively demonstrated, investigators have
challenged the premise that current membranes that possess
kilodalton sieving cutoffs >30 kDa should effectively elimi-
nate such mediators via the convective route to return the host
to immunologic homeostasis. Instead, three alternative ap-
proaches to augmenting mediator clearance have been es-
poused: (1) increasing the sieving coefficient by using
higher cutoff membranes (e.g., >60 kDa); (2) leveraging
adsorption capacity of membranes; and (3) using mem-
branes that possess mediator-specific adsorption capacity
(e.g., polymethylmethacrylate [PMMA] membranes).
Unfortunately, each of these has only been tested in adult
cohorts. A series of clinical studies have evaluated the use
of high-cutoff (HCO) membranes in adults with septic
shock, including one recent phase II trial that enrolled 30
patients and demonstrated a reduction of vasoactive infu-
sion requirements that correlated to significant reductions
in serum IL-6 levels using HCO as compared to equivalent
dosing with CVVH [92, 93]. With regards to the use of
membrane adsorption capacity, a very early study by De
Vriese et al. suggested that the principal route of cytokine
clearance in patients with sepsis was via adsorption to the
filter membrane [94]. Taking this approach, the Bellomo
group was able to demonstrate that frequent changes of
CVVH filters (3 × 3 h each) as compared to a single filter
(used over an equivalent 9 h) significantly reduced both
pro- (IL-8) and anti-inflammatory (IL-10) cytokine levels
and was associated with a faster improvement in hemody-
namics as measured by vasoactive use [95]. Building upon
the concept that adsorption could effectively remove circu-
lating mediators to attenuate AKI and other sepsis-related
organ dysfunction, researchers have combined CVVHD
with an endotoxin-adsorbing PMMA membrane to reduce
circulating cytokines in the hopes of attenuating organ
dysfunction [96]. It is highly anticipated that the comple-
tion of a number of either on-going or recently completed
trials comparing these various strategies to traditional
methodologies will provide clinicians with optimal strate-
gies for managing sepsis-induced AKI—as well as other
end-organ dysfunction. These studies are almost exclusive-
ly being performed in adults with sepsis who not only have
different sepsis-induced hemodynamic profiles and
development-dependent gene expression and immune func-
tion, but also have different physiologic responses to extra-
corporeal CRRT based on size, blood flow rates and con-
sequently on dosing. Thus, it behooves the pediatric ne-
phrology community to partner with intensive care and
other colleagues to collaborate in an effort to examine
similar therapeutic questions in the pediatric sepsis cohort.
Conclusions
Our understanding of the pathophysiology of sepsis has grown
substantially over the past two decades. While the immune
response to pathogen invasion is a critical function that enables
the host to contain and eradicate infections, dysregulation of
both the pro- and anti-inflammatory components of this re-
sponse substantially alter host physiology with consequent
effects on end-organ function. The kidney is one of the principal
targets of this pathophysiology and preserving its function in
the setting of sepsis remains a fundamental challenge that
necessitates both further understanding of the pathophysiologic
mechanisms and the renal responses to therapeutic interven-
tions. Furthermore, AKI (as well as ESRD) appears to place the
host at greater risk for developing infectious complications so
that attention must be paid to measures directed at preventing
triggers of infections/sepsis in this at-risk cohort. In the event
that AKI progresses to the point of needing RRT, further
understanding of the ability of extracorporeal approaches to
modulate the immune system during sepsis is necessary.
Thus, several areas of on-going inquiry must be pursued to
further advance our ability to successfully avoid or manage
sepsis-induced AKI, as has been suggested by others, includ-
ing: optimizing animal models that better mimic human pathol-
ogy, determining the role of innate and adaptive immunity in
sepsis-induced AKI and its potential modulation by
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extracorporeal approaches, identifying better scoring method-
ologies and biomarkers to identify AKI earlier, and examining
the impact of the various therapeutic interventions directed at
reducing circulating mediators that are responsible for end-
organ injury that includes, but is not limited to, the kidney
[97]. It is time for a multi-disciplinary approach to advancing
both our pathophysiologic understanding of the mechanisms as
well as the optimal therapeutic strategies that can attenuate the
devastating consequences of sepsis-induced AKI in pediatrics.
Open Access This article is distributed under the terms of the Creative
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